India hospital accused of misleading people in Glenmark trial without consent

Indian flag
India’s Central Drugs Standard Control Organization has dispatched two inspectors to determine any violations. (Yann Forget/Wikimedia Commons/CC BY-SA 3.0)

A hospital in India has been accused of misleading over a dozen people into joining a clinical trial of a Glenmark Pharmaceuticals painkiller without their consent, drawing an investigation from the country’s drug regulators, according to an article by The Economic Times.

Both the Malpani Multispecialty Hospital in Jaipur and Glenmark deny the allegations. A Glenmark spokesperson told FierceCRO the company has decided to immediately suspend trial operations at the hospital site and will fully cooperate with authorities. The recently initiated phase 2b study of GRC 27864 in moderate osteoarthritis pain has been initiated at 23 sites across India.

India’s Central Drugs Standard Control Organization has dispatched two inspectors to determine any violations in clinical trial procedures and regulations, according to The Economic Times. In addition, the local state health and welfare department has begun conducting its own investigation.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

According to the reported allegations, several people from a nearby village were told they would find work at the hospital, but were instead given medication. The Times of India also reported missing packets of drugs for the study, and 17 laborers were later sent to a government-run health center complaining of uneasiness and headache.

The hospital, meanwhile, said it turned the people away after they were found to be too young to participate in the trial.

“Malpani Hospital has enrolled only three patients in this trial and no adverse reactions have been reported so far,” said the Glenmark spokesperson.

According to a previous company release (PDF), Glenmark was granted permission for the placebo-controlled study by the CDSCO in January, with plans to enroll 624 patients with osteoarthritis of the knee and hip for 12 weeks and evaluate three doses compared to placebo.

Suggested Articles

Philips is cementing its commitment to becoming a healthcare technology provider, with plans to split off or sell its consumer appliances division.

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.